Heinig, Roland http://orcid.org/0000-0002-4645-5428
Eissing, Thomas http://orcid.org/0000-0003-4378-3423
Funding for this research was provided by:
This work was funded by Bayer AG, Wuppertal, Germany.
Article History
Accepted: 20 September 2023
First Online: 24 October 2023
Declarations
:
: This work was funded by Bayer AG, Wuppertal, Germany. Editorial support, including fact checking, referencing, figure preparation, formatting, proofreading, and submission was provided by Moamen Hammad, PhD, Ian Norton, PhD, and Melissa Ward, BA, of Scion, London, UK, supported by Bayer AG, Wuppertal, Germany according to Good Publication Practice guidelines (ExternalRef removed).
: RH and TE are employees of Bayer AG. In addition, RH and TE have stock in Bayer AG.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the studies.
: Not applicable.
: Availability of the data underlying this publication will be determined later according to Bayer’s commitment to the EFPIA/PhRMA principles for responsible clinical trial data sharing. This pertains to scope, time point, and process of data access. As such, Bayer commits to sharing, upon request from qualified scientific and medical researchers, participant-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in participants for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 1, 2014. Interested researchers can use ExternalRef removed to request access to anonymized participant-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsor’s section of the portal. Data access will be granted to anonymized participant-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that participant privacy is safeguarded.
: Not applicable.
: All authors drafted the article and revised it critically for important intellectual content and provided final approval of the published version.